Evolving knowledge and therapy of inflammatory bowel disease

  title={Evolving knowledge and therapy of inflammatory bowel disease},
  author={Joshua R. Korzenik and Daniel K. Podolsky},
  journal={Nature Reviews Drug Discovery},
With recent advances in the understanding of its pathophysiology, inflammatory bowel disease has become a very active area for the development of novel therapeutic agents. New targets for biologics include cytokines involved in T-cell activation, with antibodies directed against IL-12 and interferon-γ. Selective adhesion molecule blockade has produced promising, though mixed, results. Recombinant human granulocyte–macrophage colony-stimulating factor might be effective in active Crohn's disease… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 68 extracted citations

Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases.

Journal of controlled release : official journal of the Controlled Release Society • 2014
View 7 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 120 references

A Phase 2 dose ranging double blind placebo controlled trial of alicaforsen enema in subjects with acute exacerbation of mild to moderateleftsided ulcerative colitis

S. J. van Deventer
Gastroenterology • 2005

A randomized , double - blind , placebo - controlled trial of CDP 571 , a humanized monoclonal antibody to tumour necrosis factorα , in patients with corticosteroiddependent Crohn ’ s disease

B. G. Feagan
Aliment Pharmacol . Ther . • 2005

A randomized , placebo - controlled trial of certolizumab pegol ( CDP 870 ) in active Crohn ’ s Disease

S. Schreiber
Gastroenterology • 2005

A randomized controlled trial of infliximab therapy for active ulvceraive colitis : Act 1 Trial

P. Rutgeerts
Gastroenterology • 2005

Similar Papers

Loading similar papers…